Clinical application of whole-genome sequencing for precision oncology of solid tumors

Genomic alterations in tumors play a pivotal role in determining their clinical trajectory and responsiveness to treatment. While targeted panel sequencing (TPS) has been a key clinical tool over the past decade, advancements in sequencing costs and bioinformatics have now made whole-genome sequencing (WGS) a feasible single-assay approach for almost all cancer genomes in clinical settings. This paper reports on the findings of a prospective, single-center study exploring the real-world clinical utility of WGS (tumor and matched normal tissues) with two primary objectives: 1) assessing actionability for therapeutic options, and 2) providing clarity for clinical questions. Of the 120 various solid cancer patients enrolled, 95 (79%) successfully received genomics reports within a median of 11 working days from sampling to report. Analysis of these 95 WGS reports revealed that 72% (68/95) yielded clinically relevant insights, with 69% (55/79) pertaining to therapeutic actionability, and 81% (13/16) to clinical clarity. These benefits encompass selection of informed therapeutics and/or active clinical trials with driver mutations, tumor mutational burden (TMB) and mutational signatures, pathogenic germline variants that warrant genetic counseling, and information helpful for inferring cancer origin. Our findings highlight the potential of WGS as a comprehensive tool in precision oncology and advocate for its integration into routine clinical practice to provide a complete genomic landscape for tailored cancer management.

• Publication year

  2024

• Venue

  medRxiv

• Publication date

  2024-02-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1101/2024.02.08.24302488
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The grand challenge of moving cancer whole-genome sequencing into the clinic

  2024cited by this paper
• Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)

  2023cited by this paper
• First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

  2023cited by this paper
• Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel

  2023cited by this paper
• Whole genome mutational analysis for accurate tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcinoma

  2023cited by this paper
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology-College of American Pathologists Guideline Update.

  2023cited by this paper
• Real‐world study of next‐generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan

  2023cited by this paper
• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

  2023cited by this paper
• Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

  2022cited by this paper
• Targeting HER2-positive breast cancer: advances and future directions

  2022cited by this paper
• Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

  2022cited by this paper
• Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study.

  2022cited by this paper
• Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.

  2022cited by this paper
• Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer

  2022cited by this paper
• Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US Oncology Network biomarker testing in metastatic NSCLC with first-line therapy.

  2022cited by this paper
• Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing

  2022cited by this paper
• FIGHT-101, a first-in-human study of potent and selective FGFR 1–3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

  2022cited by this paper
• KRAS mutation: from undruggable to druggable in cancer

  2021cited by this paper
• First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

  2021cited by this paper
• BWA-MEME: BWA-MEM emulated with a machine learning approach

  2021cited by this paper
• Significance and limitations of the use of next-generation sequencing technologies for detecting mutational signatures.

  2021cited by this paper
• The mutational signatures of formalin fixation on the human genome

  2021cited by this paper
• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group.

  2020influential reference
• Pan-cancer analysis of whole genomes

  2020cited by this paper
• First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

  2020cited by this paper
• Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers

  2020cited by this paper
• Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer

  2020cited by this paper
• Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.

  2019cited by this paper
• Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.

  2019cited by this paper
• Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer.

  2019cited by this paper
• Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

  2019cited by this paper
• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

  2019cited by this paper
• Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer

  2018cited by this paper
• Strelka2: fast and accurate calling of germline and somatic variants

  2018cited by this paper
• Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations

  2018cited by this paper
• Whole genome sequencing analysis for cancer genomics and precision medicine

  2018cited by this paper
• The repertoire of mutational signatures in human cancer

  2018cited by this paper
• Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing

  2018influential reference
• Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer

  2017cited by this paper
• Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

  2017cited by this paper
• HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

  2017cited by this paper
• Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

  2017influential reference
• Mutational signatures associated with tobacco smoking in human cancer

  2016cited by this paper
• The Ensembl Variant Effect Predictor

  2016cited by this paper
• Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data

  2014cited by this paper
• COSMIC (Catalogue of Somatic Mutations in Cancer)

  2014cited by this paper
• MSIsensor: microsatellite instability detection using paired tumor-normal sequence data

  2014cited by this paper
• Deciphering Signatures of Mutational Processes Operative in Human Cancer

  2013cited by this paper
• Lessons from the cancer genome.

  2013cited by this paper
• Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

  2013cited by this paper
• DELLY: structural variant discovery by integrated paired-end and split-read analysis

  2012cited by this paper
• Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database

  2008cited by this paper
• Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene

  2007cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Mitochondrial DNA mosaicism in normal human somatic cells

  2024cites this paper